Regional RV akinesia, dyskinesia or aneurysm

and 1 of the following at end diastole:.

• PLAX RVOT ≥32 mm or PLAX/BSA ≥19 mm/m².

• PSAX RVOT ≥36 mm or PSAX/BSA ≥21 mm/m².

• Fractional area change ≤33%.

Regional RV akinesia or dyskinesia or dyssynchronous contraction

and 1 of the following:

• RV EDV/BSA ≥110 mL/m² (male) or ≥100 mL/m² (female).

• RVEF ≤40%.

Regional RV akinesia, dyskinesia or aneurysm.

Regional RV akinesia, dyskinesia or aneurysm

and 1 of the following at end diastole:

• PLAX RVOT ≥29–<32 mm or PLAX/BSA ≥16–<19 mm/m².

• PSAX RVOT ≥32–<36 mm or PSAX/BSA ≥18–<21 mm/m².

• Fractional area change >33%–≤40%.

Regional RV akinesia or dyskinesia or dyssynchronous contraction

and 1 of the following (end diastole):

• RV EDV/BSA ≥100–<110 mL/m² (male) or ≥90–<100 mL/m² (female).

• RVEF >40–≤45%.

Residual myocytes <60% by morphometric analysis (or <50% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy.

Residual myocytes 60%–75% by morphometric analysis (or 50%–65% if estimated), with fibrous replacement of the RV free wall myocardium in ≥1 sample, with or without fatty replacement of tissue on endomyocardial biopsy.

Inverted T-waves in leads V1, V2 and V3 or beyond, in individuals >14 years of age (in absence of complete RBBB QRS ≥120 ms).

Inverted T-waves in leads V1 and V2, in individuals >14 years of age (in absence of complete RBBB) or in V4, V5 or V6.

Inverted T-waves in leads V1, V2, V3 and V4 in individuals >14 years of age in the presence of complete RBBB.

Epsilon wave (reproducible low-amplitude signals between end of QRS complete to onset of the T-wave) in V1–3.

Late potentials by SAECG in ≥1 of 3 parameters in absence of a QRS of ≥110 ms on standard ECG:

• Filtered QRS duration ≥114 ms.

• Duration of terminal QRS <40 µV ≥38 ms.

• Root-mean-square voltage of terminal 40 ms ≤ 20 µV.

Terminal activation duration of QRS ≥55 ms, measured from the nadir of the S-wave to the end of the QRS, including R’, in V1, V2 or V3, in absence of complete RBBB.

Non-sustained or sustained VT of LBBB morphology with superior axis.

Non-sustained or sustained VT of RVOT configuration, LBBB morphology with inferior axis or with unknown axis.

>500 PVCs per 24 hours on Holter monitoring.

First-degree relative with ARVC confirmed by TFC.

First-degree relative with ARVC confirmed pathologically at autopsy or surgery.

Identification of a pathogenic mutation categorised as associated or probably associated with ARVC in the patient under evaluation.

First-degree relative with ARVC history not possible to confirm by TFC.

First-degree relative with SCD <35 years of age due to suspected ARVC.

Second-degree relative with ARVC confirmed by TFC or pathologically.